Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Curr HIV/AIDS Rep ; 13(2): 116-24, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26898645

RESUMEN

The past 3 years have marked a transition from research establishing the safety and efficacy of HIV preexposure prophylaxis (PrEP) to questions about how to optimize its implementation. Until recently, PrEP was primarily offered as part of randomized controlled trials or open-label studies. These studies highlighted the key components of PrEP delivery, including regular testing for HIV and other sexually transmitted infections (STIs), adherence and risk-reduction support, and monitoring for renal toxicity. PrEP is now increasingly provided in routine clinical settings. This review summarizes models for PrEP implementation from screening through initiation and follow-up, focusing on the strengths and weaknesses of three delivery systems: a health maintenance organization, an STI clinic, and a primary care practice. These early implementation experiences demonstrate that PrEP can be successfully delivered across a variety of settings and highlight strategies to streamline PrEP delivery in clinical practice.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Emtricitabina/uso terapéutico , Infecciones por VIH/prevención & control , Profilaxis Pre-Exposición/métodos , Tenofovir/uso terapéutico , Instituciones de Atención Ambulatoria , Atención a la Salud , Infecciones por VIH/tratamiento farmacológico , Sistemas Prepagos de Salud , Humanos , Atención Primaria de Salud , Conducta de Reducción del Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA